Latest Coya Therapeutics News & Updates

See the latest news and media coverage for Coya Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Coya Therapeutics

Clinical-stage biotechnology company developing regulatory T-cell therapies

coyatherapeutics.com

Headquarters: Houston, United States
Founded year: 2020
Company type: Private company
Number of employees: 2–20
Industry: Pharmaceuticals

Last updated Today

Latest news about Coya Therapeutics

In short: Coya Therapeutics advanced its COYA 302 clinical trials for ALS and FTD while securing significant funding and FDA Fast Track status.

Company announcements

September 8 Coya Therapeutics

Coya Therapeutics publishes preclinical results for COYA 303

The study combines IL-2 and a GLP-1 agonist to treat neurodegenerative diseases like ALS, FTD, and Alzheimer's.

August 11 Coya Therapeutics

Coya Therapeutics reports second quarter 2026 financial results

The company highlighted COYA 302 progress, including FDA Fast Track designation, and reported $43.2 million cash, enough to fund operations into 2027.

June 26 Coya Therapeutics

Coya Therapeutics CEO discusses FDA Fast Track for COYA 302

The interview covers the ALSTARS Phase 2 trial in ALS and plans for FTD expansion.

June 8 Coya Therapeutics

Coya announces first ALSTARS trial extension cohort

Patients completing the placebo phase now receive COYA 302 in the blinded extension.

Media coverage

August 11 Yahoo Finance

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...

June 11 The Globe and Mail

Coya Therapeutics Establishes $30 Million ATM Equity Program

Detailed price information for Coya Therapeutics Inc (COYA-Q) from The Globe and Mail including charting and trades.

June 10 NeurologyLive

Phase 3 Data Levacetylleucine Data in Niemann-Pick, FDA Requests Data for Deramiocel to Fulfill Submission, COYA 302 and Frontotemporal Dementia | NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Recently announced data from a small-scale, investigator-initiated trial showed that treatment with COYA 302 (Coya Therapeutics), a combination of low-dose interleukin-2 (IL2) plus CTLA-4 Ig...

June 8 Yahoo Finance

Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the initiation of the...

Never miss news about Coya Therapeutics

Track Coya Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Coya Therapeutics competitors & trending companies

Browse news for competitors to Coya Therapeutics and other trending companies.